Hycroft Mining Holding Corporation (NASDAQ:HYMC) reported $211 million in unrestricted cash and no debt in its third-quarter update, supporting continued exploration and development work at its Hycroft mining project.
AllianceBernstein Holding (NYSE:AB) reported third-quarter 2026 adjusted earnings of $0.88 per unit, up 2.3% year over year, as net revenues increased 7.8% to $1.226 billion.
Ares Capital (NASDAQ:ARCC) declared a fourth-quarter dividend of $0.48 per share as third-quarter GAAP net income fell to $319 million from $404 million a year earlier.
Daqo New Energy (NYSE:DQ) reported third-quarter 2026 revenue of $194.2 million as polysilicon shipments increased, narrowing its net loss to $52.9 million from $81.2 million in the previous quarter.
Smithfield Foods (NASDAQ:SFD) reported fiscal third-quarter operating profit of $127 million, down from $310 million a year earlier, as sales fell 8.3% to $3.4 billion for the quarter ended September 27, 2026.
Cementos Pacasmayo (NYSE:CPAC) reported third-quarter 2026 EBITDA of S/233.1 million, up 45.1% from the same quarter in 2025, as revenue and sales volumes increased.
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) received European Union approval for Enhertu as an adjuvant treatment for eligible adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.
NVIDIA (NASDAQ:NVDA) plans to invest $3 billion in Meta’s equity offering as the companies expand their collaboration on AI models, computing infrastructure and agent development.
Pharming Group (NASDAQ:PHAR) reported preliminary third-quarter 2026 revenue of $117.6 million, up 21% year over year, as operating profit rose 89% to $29.9 million.
Innate Pharma (NASDAQ:IPHA) announced that high-level data from the PACIFIC-9 Phase 3 trial are now expected in the first half of 2027, following a timeline revision by AstraZeneca (NYSE:AZN).
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
